FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
Telix today announces its financial results for the year ended December 31,...
Read moreLatest News
Category: ASX
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
Telix today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging...
Read moreTelix Full Year Results 2025 Investor Webcast Notification
Telix advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026...
Read more
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Telix provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4...
Read more
Presentation to J.P. Morgan Healthcare Conference
Telix is pleased to provide a copy of the presentation that will be delivered by Dr. Christian Behrenbruch, Managing Director and Group CEO at the 44th Annual J.P. Morgan Healthcare Conference...
Read more
ZIRDOSE-CP Study of TLX250-CDx published in EJNMMI Research: Confirms Favorable Safety and Tolerability Profile in Chinese patients
Telix today announces that final results from the ZIRDOSE-CP Phase 1 study of TLX250-CDx (Zircaix®, 89Zr-girentuximab) PET imaging in Chinese patients with suspected clear cell renal cell carcinoma (ccRCC) have been published...
Read more
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA...
Read more
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
ASX,
Telix today provides a precision medicine portfolio update in relation...
Read more
ProstACT Global Study: Status
Telix today provides an update to confirm the current status of the ProstACT Global Phase 3 study of its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in...
Read more
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated...
Read more